PD42-11 THE SWITCHING PHENOTYPE AND INTRATUMOR PLASTICITY IN BLADDER CARCINOMA: A MONO-INSTITUTIONAL ANALYSIS OF 211 MUSCLE-INVASIVE CARCINOMA WITH CONSIDERATIONS FOR THERAPY

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology II (PD42)1 Sep 2021PD42-11 THE SWITCHING PHENOTYPE AND INTRATUMOR PLASTICITY IN BLADDER CARCINOMA: A MONO-INSTITUTIONAL ANALYSIS OF 211 MUSCLE-INVASIVE CARCINOMA WITH CONSIDERATIONS FOR THERAPY Piergiuseppe Colombo, Miriam Cieri, Paolo Zucali, Camilla De Carlo, Grazia Elefante, Rodolfo Hurle, Massimo Lazzeri, Federica D'Antonio, Laura Giordano, Matteo Perrino, Giorgio Guazzoni, and Luigi Terracciano ColomboPiergiuseppe Colombo More articles by this author , CieriMiriam Cieri ZucaliPaolo Zucali CarloCamilla Carlo ElefanteGrazia Elefante HurleRodolfo Hurle LazzeriMassimo Lazzeri D'AntonioFederica D'Antonio GiordanoLaura Giordano PerrinoMatteo Perrino GuazzoniGiorgio Guazzoni TerraccianoLuigi View All Author Informationhttps://doi.org/10.1097/JU.0000000000002056.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION OBJECTIVE: Urothelial carcinoma (UC) is a heterogeneous disease the major intrinsic molecular categories identified are: Basal (B) Luminal (L). This study first evaluating presence an intra-tumor phenotypical plasticity (switch) between superficial deep component UC using immune-phenotypical score classification (Piescore) in mono-institutional cohort patients (pts) treated with transurethral resection (TURB) radical cystectomy (RC) its prognostic implications. METHODS: To stratify L, B, Mixed (M) or Neu-like (NE-L) tumors, TURB specimens pT2-HGUC from pts subsequently underwent RC were analyzed markers CD44, CK5/6, CK20 pPARg (pTa/T1) (muscle-invasive) tumor. The Piescore B L types if at least 3/4 consistent specific phenotype; M 1/2 present simultaneously; NE-L all 4 negative. increase specificity analysis, 10 selected cases investigated RT-PCR. RESULTS: From 2000 2014, enrolled. Superficial showed phenotype 99 (46.1%), 61 (28.9%), 33 (15,6%) 18 (8.5%) pts, respectively. Deep 95 (45%), 12 (5.7%) 43 (20.4%) switching was observed 80/211 (38%) (42/80, 52.5%) (20), (16), (6); (29/80, 36.2%) (21), (3), (5). completely lost CK20/pPARg (35/42, 83.3%) component: 16 switched 19 NE-L. Only 6/61 (9,8%) other phenotypes. Among NE-L, (22.2%) (3) (1) phenotype. Papillary tumors more frequently than not-papillary (52/112, 46.4% vs 26/99, 26.3%) (p=0.0385). Overall, switch did not correlate OS PFS. protective effect CD44 expression (p=0.0016) PFS (p=0.0042) observed. CONCLUSIONS: system able reveal phenotypic through evaluation side same tumor, RT-PCR added robustness our study. but group. variability has therapeutic implications partially explains sensitivity subset carcinomas chemotherapy. Good responders could be "non-real" UCs which, phenotype, acquire such as CD44. Source Funding: No © 2021 American Urological Association Education Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e729-e729 Advertisement Copyright Permissions© Inc.MetricsAuthor Information Expand Loading ...